Compounders Research Compare

Climb Bio, Inc.(CLYM)

Biotechnology · Wellesley Hills, MA

$11.05Daily change unavailable

Delayed quote: Oct 6, 2026, 9:34 AM EDT

About Climb Bio, Inc.

Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.

Wellesley Hills, MA

28 employees

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Aoife Brennan BCh MMSc

View full financials

EV/Sales Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/Sales ratio is N/A as of 2026-10-06T13:36:05.754Z.

Stored calculation inputs

Calculation as of: 2026-10-06T13:36:05.754Z.

Quote observation: 2026-10-06T13:34:50.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 632,756,150
Total debt · period ending 2026-06-30: 1,314,000
Cash · period ending 2026-06-30: 44,107,000
TTM revenue · period ending 2026-06-30: 0

FMP input reference: 979ff17a100a324a490b4ea8bab969f4c23ca35a684dd985742eca9c7cd70937

EV/EBITDA|P/S Ratio|Revenue|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

CLYM EV/Sales Ratio Metrics

EV/SALES RATIO

N/A

CLYM Competitors' EV/Sales Ratio

Climb Bio, Inc.

Current

Market Cap

$632.76M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Fulgent Genetics, Inc.

Market Cap

$639.87M

EV/Sales Ratio

1.92x

TTM Avg

1.86x

3Y Avg

1.97x

5Y Avg

1.94x

Aura Biosciences, Inc.

Market Cap

$641.49M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AngioDynamics, Inc.

Market Cap

$645.65M

EV/Sales Ratio

1.85x

TTM Avg

1.55x

3Y Avg

1.11x

5Y Avg

1.54x

4D Molecular Therapeutics, Inc.

Market Cap

$666.00M

EV/Sales Ratio

6.90x

TTM Avg

3080.33x

3Y Avg

3087.28x

5Y Avg

1898.38x

Ironwood Pharmaceuticals, Inc.

Market Cap

$596.64M

EV/Sales Ratio

2.35x

TTM Avg

3.07x

3Y Avg

3.40x

5Y Avg

3.86x

OrthoPediatrics Corp.

Market Cap

$593.84M

EV/Sales Ratio

2.64x

TTM Avg

2.20x

3Y Avg

3.12x

5Y Avg

5.45x

Annexon, Inc.

Market Cap

$681.19M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Aclaris Therapeutics, Inc.

Market Cap

$575.41M

EV/Sales Ratio

67.68x

TTM Avg

53.58x

3Y Avg

21.24x

5Y Avg

46.54x

Faeth Therapeutics, Inc.

Market Cap

$693.14M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/SALES RATIO	TTM	3Y	5Y
Climb Bio, Inc. (CLYM)	$632.76M	N/A	N/A	N/A	N/A
Fulgent Genetics, Inc. (FLGT)vs ›	$639.87M	1.92x	1.86x	1.97x	1.94x
Aura Biosciences, Inc. (AURA)vs ›	$641.49M	N/A	N/A	N/A	N/A
AngioDynamics, Inc. (ANGO)vs ›	$645.65M	1.85x	1.55x	1.11x	1.54x
4D Molecular Therapeutics, Inc. (FDMT)vs ›	$666.00M	6.90x	3080.33x	3087.28x	1898.38x
Ironwood Pharmaceuticals, Inc. (IRWD)vs ›	$596.64M	2.35x	3.07x	3.40x	3.86x
OrthoPediatrics Corp. (KIDS)vs ›	$593.84M	2.64x	2.20x	3.12x	5.45x
Annexon, Inc. (ANNX)vs ›	$681.19M	N/A	N/A	N/A	N/A
Aclaris Therapeutics, Inc. (ACRS)vs ›	$575.41M	67.68x	53.58x	21.24x	46.54x
Faeth Therapeutics, Inc. (FTH)vs ›	$693.14M	N/A	N/A	N/A	N/A

Understanding EV/Sales

Enterprise Value (EV) = Market Cap + Total Debt - Cash

Sales = Total Revenue (TTM)

EV/Sales is commonly used because:

It works for unprofitable companies where P/E doesn't apply
Revenue is harder to manipulate than earnings
It supports comparisons across companies at different profitability stages
It is frequently used for software and other revenue-growth-focused companies

Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.

EV/Sales Ratio Formula & Definition

EV/Sales = Enterprise Value / Revenue (TTM)

Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/EBITDA P/S Ratio Revenue All Metrics